Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1998-4-29
|
| pubmed:abstractText |
Skin loss due to burns and ulcers is a major medical problem. Bioengineered skin substitutes that use cultured keratinocytes as an epidermal layer with or without analogues of the dermis are one strategy for skin repair. However, none can achieve definitive wound closure, function, or cosmesis comparable to split-thickness autografts. Moreover, autograft donor sites, which require time to heal, may be limited or have attendant problems such as infection or functional/cosmetic deficiencies. To determine if the performance of composite skin grafts of keratinocytes on a dermal analogue could be enhanced, human keratinocytes were genetically modified to overexpress platelet-derived growth factor A chain (PDGF-A). Composite grafts of modified keratinocytes seeded onto acellular dermis, prepared from cryopreserved cadaver skin, secreted PDGF-AA protein in vitro [90 ng/graft (1.5 x 1.5 cm)/24 hr]. To test their performance in a wound healing model, composite grafts were transplanted to full-thickness excisional wounds on the back of athymic mice. PDGF-A grafts formed a stratified differentiated epidermis similar to control grafts. The acellular dermis was repopulated with host fibrovascular cells and by day 7, the PDGF-A grafts had significantly more cells in the dermis and increased staining for murine collagen types I and IV. At this early time point, wound contraction was also significantly inhibited in PDGF-A grafts versus control grafts. Thus, PDGF-A overexpression improves graft performance during the first critical week after transplantation.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1043-0342
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
529-39
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:9525314-3T3 Cells,
pubmed-meshheading:9525314-Animals,
pubmed-meshheading:9525314-Cells, Cultured,
pubmed-meshheading:9525314-Coculture Techniques,
pubmed-meshheading:9525314-Collagen,
pubmed-meshheading:9525314-Culture Techniques,
pubmed-meshheading:9525314-Epidermis,
pubmed-meshheading:9525314-Genetic Vectors,
pubmed-meshheading:9525314-Graft Survival,
pubmed-meshheading:9525314-Humans,
pubmed-meshheading:9525314-Keratinocytes,
pubmed-meshheading:9525314-Lac Operon,
pubmed-meshheading:9525314-Mice,
pubmed-meshheading:9525314-Mice, Nude,
pubmed-meshheading:9525314-Platelet-Derived Growth Factor,
pubmed-meshheading:9525314-Retroviridae,
pubmed-meshheading:9525314-Skin,
pubmed-meshheading:9525314-Skin Transplantation,
pubmed-meshheading:9525314-Wound Healing
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft.
|
| pubmed:affiliation |
Surgical Services, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|